TP53 and ovarian carcinoma: Cisplatin-sensitive IGROV-1 and -resistant IGROV-1/Pt1 ovarian carcinoma cell lines were used because the resistant variant displays clinically relevant features, i.e. TP53 mutation, survival pathway deregulation 15, 17, 27, 28.